Balanced Portfolio Rebalance
Date: 19/12/2024
*** GENERAL ADVICE ONLY***
Take Profit Telix (TLX) +34%, – TLX has been in a steady uptrend since entering but has hit our first price target of $25. So time to take profit in TLX and switch to another biotech
Buy Clarity Pharmaceuticals (CU6) – Clarity has been falling since hitting a highs around $8.50 in September and dropped as low as $4.50. This is roughly a 50% retracement which is why it found some support at that level. In the last few days CU6 announced an expansion of their pipeline which the market has taken positively. So this gives us an opportunity to buy CU6 at levels where the downside risk is easy to manage
BUY CU6
BUY Clarity Pharmaceuticals (CU6)
Clarity has developed a proprietary fibroblast activation protein (FAP)- targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and treatment of cancer.
• The product, termed SAR- bisFAP, has shown strong tumour targeting, retention and pharmacokinetic data to date in pre- clinical models.
• FAP is expressed widely across a range of malignancies, opening a very large pan- cancer opportunity for both imaging and treatment of various cancers.
• Clarity continues to develop a range of novel products through its Discovery Program with strong patent protection aimed at improving treatment outcomes in indications with high unmet needs.
Disclaimer: The recommendation given is general advice only. It does not take into account your personal objectives, financial situation, or specific needs. This information should not be your sole resource when making such decisions. We strongly recommend you to seek the advice of financial, taxation, and legal professionals before finalising any investment decisions.